Photo from Prime Medicine/X
May 1, 2024, 12:12
FDA has cleared Prime Medicine’s PM359 for the treatment of chronic granulomatous disease
Prime Medicine shared on X/Twitter:
“We are pleased to announce that FDA has cleared our IND application for PM359 for the treatment of chronic granulomatous disease (CGD), enabling Prime to initiate its Phase 1/2 clinical trial in the US. Details.”
Source: Prime Medicine/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 23, 2025, 02:12
Feb 23, 2025, 02:08
Feb 23, 2025, 01:54
Feb 23, 2025, 01:46
Feb 23, 2025, 01:42
Feb 23, 2025, 01:28